Hilltop Leaf

What Hilltop Leaf does

Hilltop Leaf is a privately-held UK medicinal cannabis producer operating as Hilltop Leaf Holdings Ltd, headquartered in Glasgow with a large-scale production facility in southern Scotland. The company cultivates and extracts cannabis to supply medicinal cannabis products into the UK market as a domestic alternative to imported supply. Its sole product line — medicinal cannabis — is produced at an 11,000 sq m facility built to support its stated ambition of supplying over 10% of the UK medicinal cannabis market.

The business is built on a regulated, capital-intensive production model: the company holds the necessary UK cannabis cultivation and extraction licenses, has deployed approximately £4.7 million in combined equity, SEIS, and grant funding to date, and distributes directly to healthcare providers and patients across the UK. Capital partners include Traditum Private Equity (lead £2M round, January 2023), private investors participating in a 2021 SEIS round exceeding £2 million, and South of Scotland Enterprise (£735,000 grant). The go-to-market is a single direct-distribution channel targeting the UK medicinal cannabis market.

The company is led by co-founder and CEO Hamish Clegg, co-founder and CPO Will Ewart, co-founder and Chairman Neil Ewart, and CFO Edward Browne. As of the latest reporting, Hilltop Leaf operates with 1–10 employees and was funding its first commercial sales with the January 2023 raise. Revenue has not been disclosed, and no AI, software, or technology partnerships are indicated; the competitive proposition rests on regulatory licensing, domestic supply proximity, and scale of the Scottish production asset.

Name

Hilltop Leaf

Legal name

Hilltop Leaf Holdings Ltd

Website

https://hilltopleaf.com

Company type

Private

Founded year

2021

Operating status

Operating

Headcount range

1–10 employees

Short description

Hilltop Leaf is a private UK medicinal cannabis cultivator and extractor, operating an 11,000 sq m production facility in southern Scotland to supply locally produced cannabis-based medicinal products as a domestic alternative to imports.

Ownership category

akta.pro rank

Product category

Medicinal Cannabis

NAICS

Medicinal and Botanical Manufacturing (325411)

SIC

Medicinal Chemicals & Botanical Products (2833)

akta.pro primary industry

Medicinal Plant Farming (Botanical/Pharmaceutical Crops) (AFAGAGAE)

Keywords

• Medicinal cannabis cultivation
• Cannabis extraction services
• Pharmaceutical cannabis manufacturing
• UK medical cannabis supply
• Cannabis-based medicinal products

Headquarters

HQ city

Glasgow

HQ country

United Kingdom

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Operations, Supply Chain, Infrastructure, Personnel, Technology or R&D, Marketing or Sales

Revenue model

1. Medicinal cannabis product sales: Revenue generated from the sale of locally-produced medicinal cannabis products to the UK market, serving as an alternative to imported cannabis products.

Distribution channels1 record

Core offering

Hilltop Leaf cultivates and extracts medicinal cannabis at a large-scale 11,000 sq m production facility in southern Scotland, producing locally-grown cannabis-based medicinal products for the UK market. The company holds the necessary UK licenses for cannabis cultivation and extraction and supplies its products as a domestic alternative to imported medicinal cannabis, targeting more than 10% of the UK medicinal cannabis market.

Product overview

Hilltop Leaf is a medicinal cannabis cultivation and extraction company operating as a single-product producer. The company operates a large-scale 11,000 sq m production facility in southern Scotland, producing locally-grown medicinal cannabis to supply the UK medicinal cannabis market. The company holds necessary licenses for cultivation and extraction operations and aims to compete with international cannabis producers by offering reliable, domestically-produced medicinal cannabis products.

Differentiator

Problem solved

Functional benefit

Products and services

• Hilltop Leaf Medicinal Cannabis Products Locally cultivated and extracted medicinal cannabis products produced at Hilltop Leaf's 11,000 sq m facility in southern Scotland, supplied to the UK medicinal cannabis market as a domestic alternative to imported cannabis-based medicinal products for patients and healthcare providers.

Segments1 record

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Scale indicators4 records

Recent moves7 records

Expansion highlights4 records

Emerging players

• Oxford Cannabinoid Technologies: Oxford Cannabinoid Technologies is a UK-based cannabinoid pharmaceutical R&D company listed on the London Stock Exchange. It is comparable as a UK-domiciled medicinal cannabis business, though its model is more drug-discovery oriented than cultivation.
• Ananda Developments: Ananda Developments is a UK-based company developing cannabinoid medicines for chronic pain indications. It overlaps with Hilltop Leaf in targeting UK medicinal cannabis end markets, though its focus is more on clinical-stage pharmaceutical development than cultivation.

Broad incumbents

• Aurora Cannabis: Aurora Cannabis is a large Canadian licensed producer with European operations and distribution into the UK. It is comparable as an established imported competitor whose product Hilltop Leaf is explicitly trying to displace.
• Curaleaf International: Curaleaf International is the international arm of Curaleaf Holdings, supplying medicinal cannabis across Europe including the UK. It is a comparable incumbent competing for the same UK prescription volumes that Hilltop Leaf is targeting.
• GW Pharmaceuticals (Jazz Pharmaceuticals): GW Pharmaceuticals, now owned by Jazz Pharmaceuticals, is the UK pioneer of approved cannabinoid medicines (Sativex, Epidiolex). It is the most established UK-based medicinal cannabis company and a direct reference point for regulatory and commercial benchmarks.
• Tilray Brands: Tilray is a major global cannabis company with established distribution into European and UK medicinal cannabis channels. It is a relevant comparator for pricing, import competition, and end-market dynamics in the UK.

Direct peers

• Glass Pharms: Glass Pharms is a UK medicinal cannabis producer building a domestic cultivation and manufacturing footprint for the UK prescription market. It competes head-to-head with Hilltop Leaf for UK prescriber share and is a useful operational comparable.
• Celadon Pharmaceuticals: Celadon Pharmaceuticals is a UK-based medicinal cannabis cultivator focused on supplying the domestic prescription market. It is the closest UK peer to Hilltop Leaf, sharing the cultivation-for-UK-prescriptions model and competing for the same patients and prescribers.
• Kanabo Group: Kanabo Group is a UK-headquartered medicinal cannabis company focused on cannabis-based medicines and CBD wellness products. It targets a similar UK patient and prescriber base and is comparable in stage and regulatory positioning.
• Sativa Wellness Group: Sativa Wellness Group is a UK-focused medicinal cannabis and wellness company with both product supply and clinic operations. It is relevant as a UK peer overlapping in medicinal cannabis supply to UK patients.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks5 records

Key highlights5 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Funding overview

Funding rounds3 records

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Hilltop Leaf